Last updated: 2026-09-06 01:34:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Neuropace, Inc. (NPCE) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $14.92, with a market capitalisation of $521.39M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $9.22 to $19.60. This page covers its latest market performance, valuation, price trends and company information.
$521.39M | |
$14.62 | |
$27.38 | |
$1.22 | |
$14.75 | |
66.34K | |
-- | |
-- | |
$19.60 | |
$9.22 | |
-- | |
-- |
Neuropace, Inc. (NPCE) last closed at $14.75 as of 2026-09-04 23:31:00, unchanged from the previous close of $14.75.
During the latest regular trading session, NPCE traded between $1.22 and $27.38, with a volume of 66.34K shares. The closing price was near the middle and near the middle of its 52-week range.
Over the past seven days, Neuropace, Inc. (NPCE) moved from $14.41 to $14.92, representing a gain of 3.54% ($0.51).
The stock traded between $14.44 and $14.93 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 136.59 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 54.9%
NPCE is currently trading at $14.92, placing it 54.9% of the way from its 52-week low of $9.22 to its 52-week high of $19.60. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 220 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Neuropace, Inc. (NPCE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.